ProRx Pharma

ProRx Pharma is a clinical-stage biotechnology company focused on the development of hypoxia-activated prodrugs (HAPs) for the treatment of aggressive solid tumors. The company's core technology targets the unique physiological conditions of the tumor microenvironment, specifically the low-oxygen (hypoxic) regions that are typically resistant to standard chemotherapy and radiation. Their lead candidate, PRX-519, is designed to remain inactive in healthy tissue and convert into a potent cytotoxic agent only within these hypoxic tumor zones. By leveraging this selective activation mechanism, ProRx Pharma aims to enhance therapeutic efficacy while significantly reducing systemic toxicity. The company's research programs primarily address high-unmet-need indications such as pancreatic cancer and glioblastoma.